TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Muscle injury markers (LDH, Myoglobin, CK levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: death or MI within 42 days
Endpoint domain: Mortality/survival
Primary endpoint: death or MI within 365 days
Endpoint domain: Mortality/survival
Primary endpoint: cost-effectiveness ratios per percent increase in adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: OKS score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: WOMAC score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Forgotten Joint score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Initial eradication success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reacquisition of P. aeruginosa
Endpoint domain: Adverse events/effects
Primary endpoint: Internal anal sphincter defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient tolerance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean 25-hydroxyvitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in depression parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment completion rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Child's serum cortisol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: system understanding and manipulation ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cement leakage rates
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement according to ASAS40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in MRI-based scores for sacroiliac joint inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in MRI-based scores for spinal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of lice-free participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: late mortality
Endpoint domain: Mortality/survival
Primary endpoint: Obsessive-compulsive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: movement efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported function
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: static postural control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in past-week alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive capacity for mortality risk
Endpoint domain: Mortality/survival
Primary endpoint: Absorption of BmrhGM‐CSF into the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Procedural success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of gallstones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: measures of independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meeting long-term weight loss goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meeting long-term activity goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Effect of GLP-1 to increase insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Effect of GIP to increase insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Urinary phosphate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary sodium reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dietary acceptance and compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tramadol doses required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean decrease in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: mean total pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain of anaesthetic administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in fecal bile acid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Burdjalov scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day 30 prostate volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total operative time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time per needle insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AChE inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reductions in SNOT‐16 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Premature discontinuation due to insufficient therapeutic effect
Endpoint domain: Adverse events/effects
Primary endpoint: Variability of IOP measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in H. pylori colonies per gram tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: alcohol craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: swallowing functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: swallowing-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: S aureus-negative sinonasal culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort in discussing pregnancy with Native American women
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Degree of anchorage loss of the upper posterior teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of retraction of the upper anterior teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative infection
Endpoint domain: Adverse events/effects
Primary endpoint: Symptoms on the PCSS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FP systemic exposure (AUC(0-24))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salmeterol systemic exposure (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of respiratory depression
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of desaturation
Endpoint domain: Adverse events/effects
Primary endpoint: Relapse during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypoglycemia occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in cognitive processing speed
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Consistency in condom use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived advantages of condom use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: two-year all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Cost per pregnant woman tested for HIV and syphilis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost per woman treated for syphilis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in cerebellar white matter volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maintenance or gain of weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of second pregnancies
Endpoint domain: Mortality/survival
Primary endpoint: mean modified Emory Functional Ambulation Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality reduction by 14 days
Endpoint domain: Mortality/survival
Primary endpoint: Transfusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean erythrocyte use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: risk of treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subjective comfort scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Attitudes towards fall prevention exercise with VR
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Therapeutic efficacy of PQ against relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: work ability
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: buspirone responses to ACTH and cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mortality rate after 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Mean prolactin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: IBS SSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of successfully treated patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect compartment concentration at 50% block (EC50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect compartment equilibration rate constant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TIMI major bleeding not related to CABG within 7 days
Endpoint domain: Adverse events/effects
Primary endpoint: TIMI major or minor bleeding within 7 days
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of appropriate episodes of VT and VF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early death rate
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in snacking behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binge eating frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: waist-to-height ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subcutaneous adipose tissue (SAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: proportion of children with normal tympanograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in OMQ‐14 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: NIH improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of days of adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: use of controller inhalers as prescribed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: demonstration of perfect technique for inhaler devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery room pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery discharge times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of inguinodynia at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival without long-term respiratory or neurodevelopmental disability
Endpoint domain: Mortality/survival
Primary endpoint: serum high-density lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum low-density lipoproteins (LDLs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL/high-density lipoprotein ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Creatine kinase peak normalization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-care adherence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: exercise related self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Isoflurane consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to eye opening, extubation and ready to shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post anesthesia recovery score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete daytime continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wet days per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAD scores for anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HAD scores for depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cost per responder
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cost per patient in remission
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sleep onset latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Postoperative cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intraoperative levels of natural killer lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean pH minimum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean delta pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean areas under the pH vs. time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Requirement for dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of FJV
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum buprenorphine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum norbuprenorphine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxidised LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: oxidised LDL/LDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total control of emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea-free proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five-year RFS
Endpoint domain: Mortality/survival
Primary endpoint: Wound-healing complications
Endpoint domain: Adverse events/effects
Primary endpoint: Good to excellent results for Sanders type-IV fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of MTS
Endpoint domain: Mortality/survival
Primary endpoint: Arterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inpatient hospital charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pain-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MBS relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate anaesthesia achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative pain control (VAS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emotional reaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: loss of energy
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: risk of undergoing one or more operations within 24 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of operations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Scholastic performance in reading
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Scholastic performance in spelling
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Scholastic performance in math computation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: incident arm swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MMP-2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MMP-9 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Attendance at self-help meetings
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: cardiac output reactivity to stressors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: heart rate reactivity to stressors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total peripheral resistance (TPR) under stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diabetes-related emotional distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ADHD symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oppositional defiant disorder symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global impairment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Estimated energy expenditure (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measured energy expenditure (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-exercise energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ratio of 16-OHE1 to 2-OHE1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: General psychopathology factor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the receiver operating characteristic curve (AUROC)
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in perceived control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in interfering thoughts
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perceived Recovery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: dentist response rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: time to success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 percentage of predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Days with wheeze
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: oesophageal acid contact time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean duration of reflux events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: subjective reports of discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Grade ≥ 3 thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in substance use involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily minutes of MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4(+) T-cell decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes